胰腺癌疫苗(TeloVac)合併Gemcitabine和Capecitabine臨床III期治療

抗端粒酶疫苗III期临床已纳入1000名胰腺癌患者   前沿医学资讯网 2011-5-10  领先的肿瘤生物制药公司KAEL-GemVax近日宣布，该公司已收到独立数据监控委员会发出的正式通知，TeloVac研究招募的胰腺癌患者已超过1000名，使该试验成为世界上有史以来最大规模的胰腺癌疫苗试验。这也意味着TeloVac研究将在今年8月完成招募，试验的结果有望在2012年底得到。此项研究是一项前瞻性、随机的III期临床试验，其比较了吉西他滨（Gemcitabine）和卡培他滨（Capecitabine）的标准治疗同时或在其之后用该公司的抗端粒酶疫苗GV1001进行化疗，对于局部晚期并转移的胰腺癌患者的作用。该公司的副总裁MichelleKim在最新的报告中称，试验现已接近尾声，值得高兴的是，委员会未发现不利的副作用，也无需修改试验方案。他们同时也祝贺利物浦癌症试验中心（LiverpoolCancerTrialsUnit，LCTU）组织招募了如此多的志愿者。他们相信通过此试验将获得一个大型的结果数据库，足以对GV1001的疗效和使用性能得出有价值的结论，他们期待在试验结束后开始这项分析。

Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer ClinicalTrials.gov/ First Received on January 19, 2007; Last Updated on May 19, 2011 PRATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving more than one drug (combination chemotherapy) together with vaccine therapy may kill more tumor cells. It is not yet known whether chemotherapy is more effective with or without vaccine therapy in treating pancreatic cancer. PURPOSE: This randomized phase III trial is studying gemcitabine, capecitabine, and vaccine therapy to see how well they work compared with gemcitabine and capecitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.